Zymeworks (ZYME) Net Income (2021 - 2026)
Zymeworks (ZYME) posted Net Income of -$44.2 million for Q1 2026, down 7.17% sequentially from -$41.2 million in Q4 2025, and down 95.1% YoY from -$900.6 million in Q1 2025.
Analysis
Zymeworks (ZYME) Net Income (2021 - 2026) Analysis & Trends
Zymeworks has reported Net Income for 6 years, with the latest figure at -$44.2 million in Q1 2026.
- Quarterly Net Income fell 95.1% year-over-year to -$44.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.7 million (up 9.7% YoY) and the FY2025 annual result came in at -$81.1 million, up 33.88% from the prior year.
- Net Income declined to -$44.2 million in Q1 2026 per ZYME's latest filing, from -$41.2 million in the prior quarter.
- Over five years, Net Income peaked at $309.4 million in Q4 2022 and troughed at -$72.6 million in Q1 2022.
- A 5-year average of -$14.3 million and a median of -$29.8 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income jumped 890.33% in 2022, then plunged 104.68% in 2023.
- Over 5 years, Net Income stood at $309.4 million in 2022, then slumped by 104.68% to -$14.5 million in 2023, then tumbled by 62.31% to -$23.5 million in 2024, then slumped by 75.31% to -$41.2 million in 2025, then decreased by 7.17% to -$44.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$44.2 million, -$41.2 million, and -$19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | -45.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.02 Mn |
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |